Fiera Capital Corp Trims Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fiera Capital Corp trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,801 shares of the company's stock after selling 11,101 shares during the quarter. Fiera Capital Corp owned approximately 0.51% of Neurocrine Biosciences worth $59,546,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Norden Group LLC purchased a new stake in shares of Neurocrine Biosciences in the 1st quarter worth about $393,000. Janney Montgomery Scott LLC raised its position in Neurocrine Biosciences by 3.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,907 shares of the company's stock worth $1,228,000 after buying an additional 270 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in Neurocrine Biosciences by 32.5% during the first quarter. Daiwa Securities Group Inc. now owns 8,590 shares of the company's stock valued at $1,185,000 after purchasing an additional 2,109 shares during the period. BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Neurocrine Biosciences by 33.4% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 4,937 shares of the company's stock worth $681,000 after buying an additional 1,235 shares during the last quarter. Finally, Forsta AP Fonden grew its stake in shares of Neurocrine Biosciences by 94.3% during the 1st quarter. Forsta AP Fonden now owns 34,200 shares of the company's stock valued at $4,717,000 after purchasing an additional 16,600 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded up $1.76 during trading on Friday, hitting $125.74. The company's stock had a trading volume of 561,456 shares, compared to its average volume of 961,480. The company has a market cap of $12.73 billion, a PE ratio of 33.71 and a beta of 0.35. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98. The business's 50 day simple moving average is $118.43 and its 200-day simple moving average is $133.16.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NBIX. StockNews.com cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of Neurocrine Biosciences in a research note on Tuesday, October 29th. Guggenheim lifted their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Morgan Stanley increased their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an "overweight" rating in a research note on Friday, July 12th. Finally, HC Wainwright reissued a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.91.

Insiders Place Their Bets

In related news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company's stock, valued at $5,499,554.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director William H. Rastetter sold 14,250 shares of the company's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now owns 37,491 shares in the company, valued at $5,499,554.79. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total value of $2,120,358.00. Following the completion of the transaction, the chief financial officer now directly owns 31,528 shares of the company's stock, valued at $4,741,180.64. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,063 shares of company stock valued at $7,023,330. Insiders own 4.30% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.